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induced foci which was in accordance with the progression of 
DNA repair and the declining dose rates. The absorbed dose 
in most patients treated with 131I exceeded 20mGy in the first 
hour, and in these patients, the on-set of a fast repair 
component was observed. 
Conclusions: With the experimental results and model 
calculations presented in this work, for the first time a dose-
response relationship and a description of the time course of 
the in-vitro and in-vivo damage response after internal 
irradiation of β−-emitters could be established. 
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Purpose: In proton therapy, two major beam delivery 
techniques are used which are referenced as active and 
passive delivery strategies. In latter case, an effective dose 
distribution into tumor volume is created by pencil beam 
extracted from the accelerator exit window. To do this aim, 
the modulation is performed to produce two uniform beam 
profiles: 1) along with beam trajectory and 2) in lateral 
direction vertical to beam direction. The first dose profile 
cover tumor volume in target depth against beam direction 
and the second lateral profile include tumor volume, 
transversely. Several passive devices are utilized to create 
depth dose profile known as Spread-Out Bragg Peak (SOBP) 
and transverse dose profiles. In proton therapy, the final 
purpose is to produce a three dimensional (3D) homogeneous 
dose distribution onto the tumor volume while minimizing the 
dose to the surrounding healthy tissues around the tumor. 
Relating to moving and deforming targets, the delivery dose 
is not matched with the planned dose. 
Methods: Our goal in this work is to obtain a quantitative 
assessment of three dimensional dose distribution on the 
moving and deforming targets and surrounding normal tissues 
affected by the breathing motion. For this aim, a simulation 
study was performed using Monte Carlo FLUKA code. The 
effect of each of the parameters in a clinical passive beam 
scanning system on radiotherapy dosage was considered. The 
dose deposition from protons was simulated for fields 
designed for the treatment of dynamic, deformed and static 
tumors. 
Results: Dose distribution results of Monte Carlo method 
simulation were compared with the results obtained during 
experimental process at Cyclotron and Radioisotope Center 
(CYRIC) in Tohoku University. Final analyzed results represent 
that the uniformity of dose distribution on all given tumors 
are up to 95% of uniformity that proves a successful dose 
delivery onto tumor as well according to planned dose. The 
results of dose distribution into tumor and surrounding 
healthy tissues around the tumor for static spherical case 
regarding with deformed tumors and moving tumors were 
obtained. Conclusion: In conventional proton therapy a 
significant dose is delivered to the normal tissues in 
comparison with stationary condition without getting any 
strategy to limit ITV region such as motion gated or real-time 
tumor tracking strategies. The accuracy of dose distribution 
increasing with decreasing magnitude of deformation, moving 
and stretching of the tumor. 
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An initial design of a compact, high current Fixed Field 
Alternating Gradient accelerator has been made for the 
direct production of 99mTc and the production of a number of 
therapeutic isotopes that currently available only in limited 
quantities or not at all. These studies indicate that the FFAG 
could in principle accelerate a proton beam of up to 20mA to 
at least 30 MeV and high current alpha beams to a similar 
energy. This presentation will describe the FFAG and show 
what radioisotope yields should be possible. It will also 
outline the next steps in the project. It should be noted that 
the same basic FFAG design is being extended to the energies 
required for cancer therapy with light ion beams.   
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Purpose: Several authors point out some substantial 
differences in the biological response invoked by proton 
beam and X-rays [1][2]. Beside differences in short-term 
effects such as DNA repair [3], also some long-term cellular 
and tissue properties are differentially affected, such as 
angiogenesis [4], or metastasis  [5]. We aimed at studying the 
migratory properties of human melanoma cells after low 
doses of proton beam radiation. 
Materials/methods: BLM human melanoma cells (derived 
from lung metastasis) were irradiated with 1-5 Gy of X ray 
(300 kVp Phillips, 1Gy/min) or proton beam (58 MeV) from 
Proteus C-235 cyclotron. Cells were analyzed for migratory 
and motility properties  using time-lapse monitoring of 
individual cell movements, Boyden chamber assay and the 
wound test. To check if these effects were long-term, the 
same tests were performed  at day 20 and 40 after 
irradiation. Cell stiffness was assessed using AFM method. 
Results: BLM cells exhibited lower displacement after proton 
beam and slightly higher after X rays. Boyden chamber assay 
and wound test indicated lower migration rate after proton 
beam and higher after X rays. In agreement with these 
results, cells treated with proton beam revealed decreasing 
cell stiffeness with dose as well. 
Conclusions: In contrast to X rays, low doses of proton beam 
irradiation inhibited the long-term migratory properties 
affecting their directionality and invasion potential. 
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The requirements for early diagnostics as well as effective 
treatment of cancers constantly increase the pressure on 
development of efficient and reliable methods for targeted 
radiotherapy as well as imaging of the success of the 
treatment. Recently, new nanotechnology-based approaches 
have been explored for more efficient delivery of therapeutic 
radionuclides. Nanocarriers allow delivery of the 
radionuclides not only into the tumour tissue but all the way 
inside the tumour cells, which increases cytotoxic efficacy of 
the treatment1. 
In the aim of targeted radiotherapy and imaging, new 
methods combining radionuclides and mesoporous silicon 
(PSi) nanoparticles are being developed. PSi nanoparticles 
present major advantages for localised radiotherapy. Indeed, 
mesoporous silicon can tolerate high temperatures keeping 
its properties, which makes it an optimal material for 
particle activation. Moreover, its high adsorption capacity 
with anti-cancer drugs combined with further modification of 
the nanoparticles with tumour targeting moieties allow 
delivery of therapeutically relevant doses into the tumour 
tissue with a minimum amount of particles. By selecting 
therapeutic radionuclides that are applicable for nuclear 
imaging, trafficking of the administrated chemoradiotherapy 
nanovectors can be followed by non-invasive imaging 
whether with single emission computed tomography (SPECT) 
or positron emission tomography (PET). In order to aim these 
objectives two different approaches were implemented: 
implantation of the nuclide of interest into the PSi 
nanoparticles followed by its activation or direct 
implantation of the radioisotope of interest into PSi 
The stability of the particles in buffer solutions with different 
physiologically relevant pH as well as the stability of the 
implanted nuclei in the particles were studied. The 
developed methods, first results of these studies and 
perspectives on this new therapeutical approach will be 
presented here. 
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Purpose: Radio-guided surgery (RGS) is a technique adopted 
by the surgeon to perform a complete lesion resection, 
taking advantage from the uptake from the tumor of 
specific radiolabelled tracers. Established methods make 
use of γ emitting tracer and γ radiation detection probe. To 
extend the applicability of RGS, we are developing an 
innovative technique exploiting β- radiation [1]. It 
penetrates only a few mm resulting both in a lower required 
radio-pharmaceutical activity and the possibility to apply 
the technique also to cases with a large uptake of nearby 
healthy organs. Low background rate is also correlated with 
low medical team exposure. 
Methods: We developed and tested several prototypes of 
the intraoperative β- probe, the core made of para-
terphenyl scintillator. The readout electronics is 
portable and customized to match the surgeon needs, 
with 
 
